Background—Among providers who serve low-income and uninsured women, resistance to extending the cervical cancer screening interval following normal Pap and co-test results has been documented. Our objective was to examine provider characteristics and beliefs associated with guideline-consistent screening interval recommendations. Method—We collected cross-sectional survey data between 2009 and 2010 from 82 primary care providers in six Federally Qualified Health Centers in Illinois, USA. The relationships between characteristics, beliefs, and screening interval recommendations (1 year vs. 3 years) were tested with Pearson chi-square, negative binomial and ordered logistic regression. Results—Compared to providers who recommended annual int...
Cervical cancer screening delivery remains suboptimal. Understanding the multiple influences on use ...
OBJECTIVE:Guidelines recommend 3-year cervical cancer screening intervals to avoid unnecessary invas...
Cervical cancer is the second most common malignancy that affects women worldwide (WHO, 2011). Adher...
Background: Among providers who serve low-income and uninsured women, resistance to extending the ce...
AbstractBackgroundAmong providers who serve low-income and uninsured women, resistance to extending ...
IntroductionCurrent U.S. cervical cancer screening guidelines recommend a 3- or 5-year screening int...
Introduction Current U.S. cervical cancer screening guidelines recommend a 3- or 5-year screening in...
Abstract Aim: To determine Victorian women's knowledge of the recommended Pap test screening interva...
With increased understanding of the natural history of cervical cancer, cervical cancer screening re...
Introduction: Women have been reluctant to adopt longer than annual intervals for cervical cancer sc...
Although guidelines have recommended extended interval cervical screening using concurrent human pap...
In 2015, there were 257,524 women with cervical cancer (CC) in the United States (U.S.). CC is preve...
Introduction:Many U.S. women continue to be screened annually for cervical cancer, despite current g...
OBJECTIVES: We tested the impact of different messages about the rationale for extended cervical scr...
Following the latest update of cervical cancer screening guidelines in 2012, we estimate the prevale...
Cervical cancer screening delivery remains suboptimal. Understanding the multiple influences on use ...
OBJECTIVE:Guidelines recommend 3-year cervical cancer screening intervals to avoid unnecessary invas...
Cervical cancer is the second most common malignancy that affects women worldwide (WHO, 2011). Adher...
Background: Among providers who serve low-income and uninsured women, resistance to extending the ce...
AbstractBackgroundAmong providers who serve low-income and uninsured women, resistance to extending ...
IntroductionCurrent U.S. cervical cancer screening guidelines recommend a 3- or 5-year screening int...
Introduction Current U.S. cervical cancer screening guidelines recommend a 3- or 5-year screening in...
Abstract Aim: To determine Victorian women's knowledge of the recommended Pap test screening interva...
With increased understanding of the natural history of cervical cancer, cervical cancer screening re...
Introduction: Women have been reluctant to adopt longer than annual intervals for cervical cancer sc...
Although guidelines have recommended extended interval cervical screening using concurrent human pap...
In 2015, there were 257,524 women with cervical cancer (CC) in the United States (U.S.). CC is preve...
Introduction:Many U.S. women continue to be screened annually for cervical cancer, despite current g...
OBJECTIVES: We tested the impact of different messages about the rationale for extended cervical scr...
Following the latest update of cervical cancer screening guidelines in 2012, we estimate the prevale...
Cervical cancer screening delivery remains suboptimal. Understanding the multiple influences on use ...
OBJECTIVE:Guidelines recommend 3-year cervical cancer screening intervals to avoid unnecessary invas...
Cervical cancer is the second most common malignancy that affects women worldwide (WHO, 2011). Adher...